<!DOCTYPE html>
<html>
  <head>
    <title>Cardiovascular Disease Risk Assessment</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta charset="utf-8">
    <!-- Bootstrap -->
    <link href="//netdna.bootstrapcdn.com/bootswatch/3.2.0/flatly/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="/css/site.css" rel="stylesheet" media="screen">
    <link href="/css/syntax.css" rel="stylesheet" media="screen">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-48968311-4', 'jandecaluwe.com');
  ga('send', 'pageview');

</script>
  </head>

  <body>

    <!-- Fixed navbar -->
    <div class="navbar navbar-default navbar-fixed-top">
      <div class="container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/">Roryâ€™s notes</a>
        </div>
        <div class="navbar-collapse collapse">

          <ul class="nav navbar-nav navbar-left">
 
          </ul>

          <ul class="nav navbar-nav navbar-right">
            <li class="active"><a href="/notes/">notes</a></li>
          </ul>

        </div><!--/.nav-collapse -->
      </div>
    </div>


<div class="container">

  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
      <li><a href="/notes/">notes</a></li>
      <li><a href="/notes/cardiovascular/">cardiovascular</a></li>
      <li class="active">Cardiovascular Disease Risk Assessment</li>
  </ol>

  <div class="page-header">
 
    <h1>Cardiovascular Disease Risk Assessment</h1>
  </div>

  <div class="row">

    <div class="col-md-3" role="navigation"> 
 
      <div class="sidebar" data-spy="affix" data-offset-top="80" data-offset-bottom="60">
        <div class="well">
          <a href="#"><strong>Cardiovascular Disease Risk Assessment</strong></a>
          <div class="toc">
<ul>
<li><a href="#update-2013-nz-primary-care-handbook-2012">Update 2013: NZ Primary Care Handbook 2012</a></li>
<li><a href="#recommendations">Recommendations</a></li>
<li><a href="#cardiovascular-disease-risk-assessment">Cardiovascular disease risk assessment</a><ul>
<li><a href="#intervention">Intervention</a><ul>
<li><a href="#see-cardiovascular-risk-charts-and-table">See Cardiovascular risk charts and table</a></li>
</ul>
</li>
<li><a href="#recommended-age-to-offer-cardiovascular-risk-assessment">Recommended age to offer cardiovascular risk assessment</a></li>
<li><a href="#for-cardiovascular-risk-assessment">For cardiovascular risk assessment</a></li>
<li><a href="#secondary-causes-of-hypertension">Secondary causes of hypertension</a><ul>
<li><a href="#rare-causes-of-secondary-hypertension-consider-in-severe-or-resistant-hypertension">Rare causes of secondary hypertension - consider in severe or resistant hypertension</a></li>
</ul>
</li>
<li><a href="#what-to-measure-and-record-for-cvra">What to measure and record for CVRA</a><ul>
<li><a href="#history">History</a></li>
<li><a href="#family-history">Family History</a></li>
<li><a href="#past-medical-history">Past medical history</a></li>
<li><a href="#measure">Measure</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#estimating-5yr-cardiovascular-risk-the-charts">Estimating 5yr cardiovascular risk - the charts:</a><ul>
<li><a href="#very-high-risk-groups-6220">Very high risk groups: >20%</a></li>
<li><a href="#people-aged-35-74-yrs">People aged 35-74 yrs</a></li>
<li><a href="#people-aged-35yrs-with-known-risk-factors">People aged \&lt;35yrs with known risk factors</a></li>
<li><a href="#people-aged-6275yo-depending-on-other-risk-factors">People aged >75yo; depending on other risk factors</a></li>
<li><a href="#note-risk-charts-may-underestimate-risk-in">Note: risk charts may underestimate risk in:</a></li>
<li><a href="#microalbuminuria-definition">Microalbuminuria definition</a></li>
</ul>
</li>
<li><a href="#cardiovascular-risk-factor-management-goals">Cardiovascular risk factor management goals</a><ul>
<li><a href="#aim-of-treatment-is-to-reduce-cvd-risk">Aim of treatment is to reduce CVD risk</a></li>
</ul>
</li>
<li><a href="#lifestyle-interventions">Lifestyle interventions</a><ul>
<li><a href="#diet">Diet</a><ul>
<li><a href="#heart-foundations-nine-steps-to-eating-for-a-healthy-heart">Heart foundation's nine steps to eating for a healthy heart</a></li>
</ul>
</li>
<li><a href="#physical-activity">Physical activity</a></li>
<li><a href="#weight">Weight</a></li>
<li><a href="#smoking-cessation">Smoking cessation</a><ul>
<li><a href="#effective-smoking-interventions">Effective smoking interventions</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#medication-management">Medication Management</a><ul>
<li><a href="#lipid-lowering">LIpid lowering</a></li>
<li><a href="#lipid-lowering-for-people-with-combined-cvd-risk-between-10-20">Lipid lowering for people with combined CVD risk between 10-20%</a></li>
<li><a href="#lipid-lowering-for-people-with-combined-cvd-risk-6220">Lipid lowering for people with combined CVD risk >20%</a><ul>
<li><a href="#monitoring">Monitoring</a></li>
<li><a href="#statin-safety-monitoring">Statin safety monitoring</a><ul>
<li><a href="#interacting-medication-and-max-simvastatin-dose">Interacting medication and max. simvastatin dose</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#blood-pressure-lowering">Blood pressure lowering</a><ul>
<li><a href="#between-10-20">Between 10-20%</a></li>
<li><a href="#6220">>20%</a></li>
<li><a href="#treatment-choices">Treatment choices</a></li>
<li><a href="#monitoring_1">Monitoring</a></li>
</ul>
</li>
<li><a href="#long-term-aspirinantiplatelet-therapy">Long-term aspirin/antiplatelet therapy</a><ul>
<li><a href="#contraindications">contraindications:</a></li>
</ul>
</li>
</ul>
</li>
</ul>
</div>

        </div>
      </div>
    </div>
 
    <div class="content">
      <div class="col-md-6" role="main">
        <h4 id="update-2013-nz-primary-care-handbook-2012">Update 2013: NZ Primary Care Handbook 2012</h4>
<ul>
<li>
<p>New CVDRA equation available 2014</p>
</li>
<li>
<p>Management options discussed with all patients</p>
</li>
<li>
<p>Increasingly graded approach to the intensity of management</p>
</li>
<li>
<p>Combined risk replaces absolute risk</p>
</li>
<li>
<p><strong>Overarching principle</strong> is that intensity of interventions proportional to size of estimated cvd risk.</p>
</li>
</ul>
<h3 id="recommendations">Recommendations</h3>
<ul>
<li>
<p>All patients benefit from healthier lifestyles</p>
</li>
<li>
<p>Most patients with 5yr combined risk \&lt;10% well managed without drug treatment</p>
</li>
<li>
<p>5yr CVD risk 10-20%</p>
</li>
<li>
<p>discussion about benefits and harms of BP lowering and lipid lowering drugs</p>
</li>
<li>
<p>shared decision to initiate:</p>
<ul>
<li>
<p>lifestyle only</p>
</li>
<li>
<p>add BP dec.</p>
</li>
<li>
<p>add lipid lowering</p>
</li>
<li>
<p>ALL</p>
</li>
</ul>
</li>
<li>
<p>Most patients with CVD risk >20% benefit significantly from <em>both</em> BP and lipid lowering and antiplatelet drugs + <strong>intensive non-pharmacological interventions</strong> </p>
</li>
<li>
<p>Patients at any age with significant individual risk factors need to have them managed</p>
</li>
</ul>
<h3 id="cardiovascular-disease-risk-assessment">Cardiovascular disease risk assessment</h3>
<ul>
<li>
<p>Shared treatment decisions form basis of managing cardiovascular risk</p>
</li>
<li>
<p>Take into account: </p>
</li>
<li>
<p>individuals estimated 5yr combined CVD risk</p>
</li>
<li>
<p>magnitude of absolute benefits</p>
</li>
<li>
<p>harms of intervention</p>
</li>
</ul>
<h4 id="intervention">Intervention</h4>
<ul>
<li>
<p>Lifestyle</p>
</li>
<li>
<p>diet </p>
</li>
<li>
<p>exercise</p>
</li>
<li>
<p>smoking</p>
</li>
<li>
<p>lipid lowering</p>
</li>
<li>
<p><a href="Cardiology: hypertension">blood pressure lowering</a></p>
</li>
<li>
<p>antiplatelet medication</p>
</li>
<li>
<p><a href="Endocrine: diabetes">diabetes</a> care</p>
</li>
<li>
<p>medication after:</p>
</li>
<li>
<p><a href="Cardiology: myocardial infarction">myocardial infarction (MI)</a></p>
</li>
<li>
<p><a href="Neurology: stroke">stroke</a></p>
</li>
<li>
<p>other cardiovascular events</p>
</li>
</ul>
<h6 id="see-cardiovascular-risk-charts-and-table">See Cardiovascular risk charts and table</h6>
<h4 id="recommended-age-to-offer-cardiovascular-risk-assessment">Recommended age to offer cardiovascular risk assessment</h4>
<ul>
<li>
<p>Asymptomatic without known risk factors:</p>
</li>
<li>
<p>Men: 45yrs</p>
</li>
<li>
<p>Woman: 55yrs</p>
</li>
<li>
<p>Maori/pacific/indo-asian:</p>
</li>
<li>
<p>Men 35yrs</p>
</li>
<li>
<p>Woman 45yrs</p>
</li>
<li>
<p>People with other known risk factors or high risk of developing diabetes</p>
</li>
<li>
<p>Family history risk factors:</p>
<ul>
<li>
<p><a href="Endocrine: Diabetes">Diabetes</a> in 1st-degree relative </p>
</li>
<li>
<p>Premature CAD or ischaemic stroke in a first-degree relative (male \&lt;55yrs, female \&lt;65yrs)</p>
</li>
</ul>
</li>
<li>
<p>Personal history risk factors</p>
<ul>
<li>
<p>People who <a href="GP: smoking cessation">smoke</a> (or who have quit in last 12 months)</p>
</li>
<li>
<p><a href="Obstetrics: Gestational diabetes">Gestational diabetes</a>, <a href="Gynaecology: PCOS">PCOS</a></p>
</li>
<li>
<p>Prior <a href="cardiology: hypertension">hypertension</a> (BP >160/90)</p>
</li>
<li>
<p>Prior TC:HDL ratio >= 7</p>
</li>
<li>
<p>BMI >30 or truncal obesity: >100cm men, >90cm women</p>
</li>
<li>
<p>eGFR \&lt;60</p>
</li>
</ul>
</li>
<li>
<p>People with <a href="endocrine: diabetes">diabetes</a> (type 1 or type 2)</p>
</li>
<li>
<p>annually from time of diagnosis</p>
</li>
<li>
<p>It is reasonable to not see face-face if things have not significantly changed</p>
</li>
<li>
<p>if CVRA \&lt;5% review/reassess within the next <strong>10 years</strong></p>
</li>
</ul>
<h4 id="for-cardiovascular-risk-assessment">For cardiovascular risk assessment</h4>
<ul>
<li>
<p>Lipids</p>
</li>
<li>
<p>single <strong>non-fasting</strong> TC:HDL ratio used in calculation</p>
</li>
<li>
<p>If TC or TC:HDL >8mmol/l repeat the test</p>
<ul>
<li>There is a possibility of genetic lipid disorder if TC>8 and/or strong FHx of premature CAD</li>
</ul>
</li>
<li>
<p>HBA1c</p>
</li>
<li>
<p>Use single non-fasting HbA1c to screen for diabetes at same time as lipid profile</p>
</li>
<li>
<p>Blood pressure</p>
</li>
<li>
<p>Sitting BP measurement</p>
</li>
<li>
<p>2 seated BP measurements recommended for initial risk assessment</p>
</li>
</ul>
<h4 id="secondary-causes-of-hypertension">Secondary causes of hypertension</h4>
<ul>
<li>
<p>recent caffeine intake</p>
</li>
<li>
<p>high etoh intake</p>
</li>
<li>
<p>oestrogen and glucocorticoid administration</p>
</li>
<li>
<p>anti-inflammatory agents</p>
</li>
<li>
<p>cyclospirn</p>
</li>
<li>
<p>sympathetomimetics</p>
</li>
</ul>
<h5 id="rare-causes-of-secondary-hypertension-consider-in-severe-or-resistant-hypertension">Rare causes of secondary hypertension - consider in severe or resistant hypertension</h5>
<ul>
<li>
<p><a href="Renal: chronic kidney disease">renal disease</a></p>
</li>
<li>
<p><a href="cardiology: coarctation of aorta">coarctation of aorta</a></p>
</li>
<li>
<p><a href="Renal: Renal artery stenosis">renal artery stenosis</a></p>
</li>
<li>
<p><a href="endocrine: Phaeochromocytoma">Phaeochromocytoma</a></p>
</li>
<li>
<p><a href="endocrine: Cushings syndrome">Cushing's syndrome</a></p>
</li>
<li>
<p><a href="endocrine: conn's syndrome">Conn's syndrome</a></p>
</li>
</ul>
<h4 id="what-to-measure-and-record-for-cvra">What to measure and record for CVRA</h4>
<h6 id="history">History</h6>
<ul>
<li>
<p>Age</p>
</li>
<li>
<p>Gender</p>
</li>
<li>
<p>Ethnicity</p>
</li>
<li>
<p>Smoking status (if stopped \&lt;12/12 record as smoker)</p>
</li>
</ul>
<h6 id="family-history">Family History</h6>
<ul>
<li>
<p>Premature coronary heart disease/ischaemic stroke first deg. rel</p>
</li>
<li>
<p>male \&lt;55yo</p>
</li>
<li>
<p>female \&lt;65</p>
</li>
<li>
<p><a href="endocrine: diabetes">Type 2 DM</a></p>
</li>
<li>
<p><a href="cardiology: familial hypercholesterolaemia">Genetic lipid disorder</a></p>
</li>
</ul>
<h6 id="past-medical-history">Past medical history</h6>
<ul>
<li>
<p>Past history of cardiovascular disease</p>
</li>
<li>
<p><a href="cardiology: myocardial infarction">MI</a></p>
</li>
<li>
<p>PCI</p>
</li>
<li>
<p>CABG</p>
</li>
<li>
<p><a href="cardiology: angina">Angina</a></p>
</li>
<li>
<p><a href="Neurology: stroke">Ischaemic stroke</a></p>
</li>
<li>
<p><a href="Neurology: TIA">TIA</a></p>
</li>
<li>
<p><a href="surgery: peripheral vascular disease">Peripheral vascular disease</a></p>
</li>
<li>
<p>Genetic lipid disorder</p>
</li>
<li>
<p><a href="cardiology: familial hypercholesterolaemia">FH</a></p>
</li>
<li>
<p><a href="cardiology: Familial defective ApoB">FDB</a></p>
</li>
<li>
<p><a href="cardiology: Familial combined dyslipidaemia">FCH</a></p>
</li>
</ul>
<h6 id="measure">Measure</h6>
<ul>
<li>
<p>Average of 2 sitting BP (one if below 160/95)</p>
</li>
<li>
<p>BMI</p>
</li>
<li>
<p><a href="GP: waist circumference">Waist circumference</a></p>
</li>
<li>
<p>Non-fasting lipid profile</p>
</li>
<li>
<p>HbA1c</p>
</li>
</ul>
<h3 id="estimating-5yr-cardiovascular-risk-the-charts">Estimating 5yr cardiovascular risk - the charts:</h3>
<h6 id="very-high-risk-groups-6220">Very high risk groups: >20%</h6>
<ul>
<li>
<p>Previous CVD event</p>
</li>
<li>
<p>Some genetic lipid disorders (see above)</p>
</li>
<li>
<p><a href="endocrine: diabetes">Diabetes</a> with overt <a href="renal: diabetic nephropathy">nephropathy</a></p>
</li>
<li>
<p>ACR 30mg/mmol</p>
</li>
<li>
<p>urinary albumin 200mg/L</p>
</li>
<li>
<p>Diabetes with other renal disease causing renal impairment</p>
</li>
<li>
<p>eGFR \&lt;60</p>
</li>
</ul>
<h6 id="people-aged-35-74-yrs">People aged 35-74 yrs</h6>
<ul>
<li>
<p>Calculate 5yr risk</p>
</li>
<li>
<p>AF confers additional risk over and above</p>
</li>
<li>
<p>These groups moved up one risk group cateogry:</p>
</li>
<li>
<p>FHx of premature CAD or ischaemic stroke in 1st deg. relative</p>
</li>
<li>
<p>Maori, pacific people or indo-asian peoples</p>
</li>
<li>
<p>Diabetes with microalbuminuria, persistent proteinuria, or DM for 10yrs, or HbA1c consistently >64mmol/L</p>
</li>
</ul>
<h6 id="people-aged-35yrs-with-known-risk-factors">People aged \&lt;35yrs with known risk factors</h6>
<ul>
<li>
<p>All calculations outside age ranges of Framingham equation are approximate but can be useful</p>
</li>
<li>
<p>Age \&lt;35:</p>
</li>
<li>
<p>calculate risk as if 35yrs old</p>
</li>
<li>
<p>Low HDL\&lt;0.7mmol/L - because of risk of genetic lipid disorder</p>
</li>
<li>
<p>Known familial dyslipidaemias or suspected genetic lipid disorders</p>
</li>
<li>
<p><a href="endocrine: Type 1 DM">Type 1 DM</a>, Type 2 DM with microalbuminauria, Type 2 DM of long duration (10yrs)</p>
</li>
</ul>
<h6 id="people-aged-6275yo-depending-on-other-risk-factors">People aged >75yo; depending on other risk factors</h6>
<ul>
<li>
<p>evidence for lipid lowering in the elderly limited as primary prevention</p>
</li>
<li>
<p>harms vs benefit analysis/discussion more difficult</p>
</li>
<li>
<p>Older people gain similar relative benefit from cholesterol lowering</p>
</li>
<li>
<p>but are more likely to have absolute benefit</p>
</li>
<li>
<p>much higher pre-treatment of cardiovascular risk</p>
</li>
<li>
<p>Cormorbidity is more common</p>
</li>
<li>
<p>time available to derive benefit will be shorter</p>
</li>
<li>
<p>patients' expectations should be taken into account</p>
</li>
</ul>
<h6 id="note-risk-charts-may-underestimate-risk-in">Note: risk charts may underestimate risk in:</h6>
<ul>
<li>
<p>single risk factors:</p>
</li>
<li>
<p>TC >= 8mmol/L</p>
</li>
<li>
<p>TC:HDL ratio >= 8</p>
</li>
<li>
<p>BP consistently above 170/100 mmHg</p>
</li>
</ul>
<h6 id="microalbuminuria-definition">Microalbuminuria definition</h6>
<blockquote>
<p>excretion between 30mg and 300mg of albumin a day in the urine.  </p>
<p>less than 30mg is insignificant.  </p>
<p>more than 300mg is albuminauria or macroalbuminuria.  </p>
</blockquote>
<h3 id="cardiovascular-risk-factor-management-goals">Cardiovascular risk factor management goals</h3>
<ul>
<li>
<p>All treatment decisions should be informed by an individual's estimated 5 year combined CVD risk</p>
</li>
<li>
<p>discussion of magnitude of benefits and type and likelihood of potential harms</p>
</li>
<li>
<p>People will have their own risk thresholds</p>
</li>
</ul>
<h5 id="aim-of-treatment-is-to-reduce-cvd-risk">Aim of treatment is to reduce CVD risk</h5>
<ul>
<li>
<p>The order in which to start interventions should take into account :</p>
</li>
<li>
<p>indicidual risk factor levels</p>
<ul>
<li>it is easier to modify risk that is very abN than one that is moderatley abN</li>
</ul>
</li>
<li>
<p>potential sie effects</p>
</li>
<li>
<p>other concurrent illness</p>
</li>
<li>
<p>compliance</p>
</li>
<li>
<p>personal preference</p>
</li>
<li>
<p>Blood pressure lowering and statin medications work independently to lower risk</p>
</li>
<li>
<p>Either or both will be effective depending on the combined clinical risk</p>
</li>
<li>
<p>[]"Your heart forecast"](http://www.heartfoundation.org.nz)</p>
</li>
</ul>
<h2 id="lifestyle-interventions">Lifestyle interventions</h2>
<ul>
<li>
<p>Graded lifestyle advice is appropriate for everyone</p>
</li>
<li>
<p>Based on behavioural counselling approach</p>
</li>
<li>
<p>self-monitoring</p>
</li>
<li>
<p>training to overcome bommon barriers</p>
</li>
<li>
<p>goal setting</p>
</li>
<li>
<p>providing guidance in shopping and food prep</p>
</li>
<li>
<p>role playing</p>
</li>
<li>
<p>arranging support or referral</p>
</li>
</ul>
<h3 id="diet">Diet</h3>
<h4 id="heart-foundations-nine-steps-to-eating-for-a-healthy-heart">Heart foundation's nine steps to eating for a healthy heart</h4>
<ul>
<li>
<p>Enjoy three meals a day: little or no diary fat, meat fat or deep-fried foods</p>
</li>
<li>
<p>Fruits and/or vegetables at every meal and for most snacks</p>
</li>
<li>
<p>Whole grains, whole-grain breads or high-bibre breakfast cereals</p>
</li>
<li>
<p>Fish or dried peas, beans and soy products or a small serving of lean meat or skinned poultry at one or two meals each day</p>
</li>
<li>
<p>Low-fat milk/milk products, soy or legume every day</p>
</li>
<li>
<p>Use nuts, seeds, avocado, oils or marg instead of anilmal and coconut fats</p>
</li>
<li>
<p>Drink plenty of fluids each day - esp. water</p>
</li>
<li>
<p>Use only small amounts of sugar or salt when cooking and preparing meals, snacks or drinks</p>
</li>
<li>
<p>Mostly avoid or rarely include: butter, deep-fried and fatty foods</p>
</li>
</ul>
<h3 id="physical-activity">Physical activity</h3>
<p><a href="sports: exercise prescription">Exercise prescription</a></p>
<ul>
<li>
<p>aim is for minimum of 30 minutes moderate-intensity physical activity on most days of the week</p>
</li>
<li>
<p>history of CVD should consult doctor before they undertake vigorous physical activity</p>
</li>
<li>
<p>Vigorous activity not encouraged if:</p>
</li>
<li>
<p>Impaired LV function</p>
</li>
<li>
<p>Severe coronary artery disease</p>
</li>
<li>
<p>Recent MI</p>
</li>
<li>
<p>Significant ventricular arrhythmias </p>
</li>
<li>
<p>Stenotic valve disease</p>
</li>
<li>
<p>People with coronary artery disease should begin with low intensity and gradually increase over several weeks</p>
</li>
<li>
<p>search physical activity <a href="www.health.govt.nz">MoH</a></p>
</li>
</ul>
<h3 id="weight">Weight</h3>
<ul>
<li>
<p>if BMI >25 guidelines recommend combination of changes in:</p>
</li>
<li>
<p>food/nutrition</p>
</li>
<li>
<p>physical activity</p>
</li>
<li>
<p>behavioural strategies to support these changes</p>
</li>
</ul>
<h3 id="smoking-cessation">Smoking cessation</h3>
<p><a href="GP: smoking cessation">smoking cessation</a></p>
<ul>
<li>
<p><strong>Ask</strong> about smoking status</p>
</li>
<li>
<p><strong>Brief advice</strong> to stop and make an offer of help to quit to <strong>all</strong> smokers</p>
</li>
<li>
<p><strong>Cessation support</strong></p>
</li>
<li>
<p><strong>Document</strong> your intervention</p>
</li>
</ul>
<h5 id="effective-smoking-interventions">Effective smoking interventions</h5>
<ul>
<li>
<p>Breief advice from health pro vs. no intervention</p>
</li>
<li>
<p>Proactive telephone support vs. reactive telephone support</p>
</li>
<li>
<p>Automated text messagign vs messaging not realted to smoking</p>
</li>
<li>
<p>Face-Face, indiviidual behavioural support vs. breif advice or written materials</p>
</li>
<li>
<p>Face-face, group-based behavioural support vs breif advice or written materials</p>
</li>
</ul>
<h2 id="medication-management">Medication Management</h2>
<h3 id="lipid-lowering">LIpid lowering</h3>
<ul>
<li>
<p>TC >8 or a TC:HDL-C ratio >8 </p>
</li>
<li>
<p>Lipid lowerging treatment usually recommended regardless of combined CVD risk</p>
</li>
</ul>
<h3 id="lipid-lowering-for-people-with-combined-cvd-risk-between-10-20">Lipid lowering for people with combined CVD risk between 10-20%</h3>
<ul>
<li>
<p>Discuss benefits (and risks) of statins</p>
</li>
<li>
<p>Lifestyle</p>
</li>
<li>
<p>Repeat lipid profile 6-12 months</p>
</li>
<li>
<p>Aim: achieve moderate reduction in LDL-C</p>
</li>
<li>
<p>Consider treatable primary cause for a dyslipidaemia</p>
</li>
<li>
<p>High saturated fat diet</p>
</li>
<li>
<p>excessive EtOH</p>
</li>
<li>
<p>hypothyroidism</p>
</li>
<li>
<p>diabetes</p>
</li>
<li>
<p>liver disease</p>
</li>
<li>
<p>nephrotic syndrome</p>
</li>
<li>
<p>steroid treatment</p>
</li>
</ul>
<h3 id="lipid-lowering-for-people-with-combined-cvd-risk-6220">Lipid lowering for people with combined CVD risk >20%</h3>
<ul>
<li>
<p>statin treatment strongly recommended</p>
</li>
<li>
<p><strong>Atorvastatin: 20-40mg</strong></p>
</li>
<li>
<p>10-20% consider lower dose - <strong>simvastatin 40mg or atorvastatin 20mg</strong></p>
</li>
<li>
<p>no evidence that outcomes are improved by adding other cholesterol-lowering drugs to a statin</p>
</li>
</ul>
<h5 id="monitoring">Monitoring</h5>
<ul>
<li>
<p>non fasting lipids q3-6/12 until person stable then once/year</p>
</li>
<li>
<p>moderate reduction in LDL-C</p>
</li>
</ul>
<h5 id="statin-safety-monitoring">Statin safety monitoring</h5>
<ul>
<li>generally safe</li>
</ul>
<h6 id="interacting-medication-and-max-simvastatin-dose">Interacting medication and max. simvastatin dose</h6>
<ul>
<li>
<p>Amiodarone: 20mg</p>
</li>
<li>
<p>Verapamil: 20mg</p>
</li>
<li>
<p>Diltiazem: 20mg</p>
</li>
<li>
<p>Nicotinic acid >1g/day: 20mg</p>
</li>
<li>
<p>Amlodipine: 40mg</p>
</li>
<li>
<p>consider a simvastatin dose reduction with: fibrates, systemic fusidic acid, colchicine, renal impairment</p>
</li>
<li>
<p>Monitoring LFT not necesasry --> risk of liver toxicity negligible</p>
</li>
<li>
<p>Monitoring CK not required in those asymptomatic</p>
</li>
<li>
<p>CK for unexplained muscle pain, tenderness or weakness</p>
</li>
<li>
<p>Risk of myopathy usually dose related; increased in elderly; combination treatments</p>
</li>
<li>
<p>For muscle pain without CK rise: dose reduciton/discontinuation may be required</p>
</li>
<li>
<p>CK rise 3-10x normal with symptoms: dose reduction/discontinuation with regular weekly monitoring of symptoms and CK is appropriate</p>
</li>
<li>
<p>CK risk >10x normal with symptoms; discontinue immediately</p>
</li>
</ul>
<h3 id="blood-pressure-lowering">Blood pressure lowering</h3>
<ul>
<li>
<p>BP> 170/100 BP lowering treatment usually recommended irrespective of the combined CVD risk</p>
</li>
<li>
<p>\&lt;170/100 informed by combined cardiovascular risk</p>
</li>
</ul>
<h4 id="between-10-20">Between 10-20%</h4>
<ul>
<li>
<p>discuss benefits and risks</p>
</li>
<li>
<p>lifestyle modification</p>
</li>
<li>
<p>aim is to achieve moderate blood pressure reduction to reduce combined risk -> <strong>no target</strong></p>
</li>
</ul>
<h4 id="6220">>20%</h4>
<ul>
<li>
<p>strongly recommended</p>
</li>
<li>
<p>caution if BP \&lt;130/80</p>
</li>
</ul>
<h4 id="treatment-choices">Treatment choices</h4>
<ul>
<li>unchanged from 2012</li>
</ul>
<h4 id="monitoring_1">Monitoring</h4>
<ul>
<li>monitor q3-6/12</li>
</ul>
<h3 id="long-term-aspirinantiplatelet-therapy">Long-term aspirin/antiplatelet therapy</h3>
<ul>
<li>
<p>Should not be added if on oral anticoagulants</p>
</li>
<li>
<p>Generally <strong>Not</strong> recommended risk \&lt;20%</p>
</li>
<li>
<p>Can be considered for high-risk primary prevention: taking into account harms and benefits</p>
</li>
<li>
<p>Strongly recommended people with established cardiovascular disease</p>
</li>
</ul>
<h4 id="contraindications">contraindications:</h4>
<ul>
<li>
<p>Aspirin allergies/intolerance</p>
</li>
<li>
<p>active peptic ulceration</p>
</li>
<li>
<p>uncontrolled BP and other major bleeding risks)</p>
</li>
</ul>
      </div>
    </div>

  </div>
    

    <div class="footer">
        <p>Website powered by <a href="http://urubu.jandecaluwe.com">Urubu</a></p>
    </div>


</div> 


    <!-- jQuery (necessary for Bootstrap's JavaScript plugins) -->
    <script src="https://code.jquery.com/jquery.js"></script>
    <!-- Include all compiled plugins (below), or include individual files as needed -->
    <script src="//netdna.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js"></script>

  </body>
</html>
